Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review.
about
Treatment with echinocandins during continuous renal replacement therapyPharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic.Management of invasive candidiasis in nonneutropenic ICU patients.Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients.Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011Approaches for dosage individualisation in critically ill patients.Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis.New insights into the antimicrobial blue light inactivation of Candida albicans.Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model.Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration.Photodynamic Action Mechanism Mediated by Zinc(II) 2,9,16,23-Tetrakis[4-(N-methylpyridyloxy)]phthalocyanine in Candida albicans Cells.
P2860
Q27012864-3B326232-DD4A-4C09-84BF-A11A691E7F4DQ30936281-93E1C002-9509-4E00-89AD-C423851CBAB0Q34329290-F8AEB4B9-F874-4B35-864E-7C1CFC0563FBQ35122093-59F7C1FE-06D2-47E3-BE35-A5EC0D52CC18Q36018743-14F235FF-C593-4DBC-8471-F70CAB2E2A66Q37358623-62147A6E-288F-43F1-AAED-90B32874068FQ37544662-5B4CDF15-D654-4A52-976E-74711E13D335Q38125209-7501ABE2-0538-444E-BF68-AAED5CA56D41Q39031509-946E47E5-77FB-4CAA-916D-BA8D7743B98FQ40765147-383ACA96-9576-41C5-9F52-F08E826812C8Q41907385-41286CCC-FC83-4196-8C2B-78672B0E4449Q44311698-84DC3D0D-042A-4385-B513-D0064066C3AAQ46710093-0445ECED-A0B3-4341-817C-DD65CB902049
P2860
Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Using pharmacokinetics and pha ...... patients: a systematic review.
@en
Using pharmacokinetics and pha ...... patients: a systematic review.
@nl
type
label
Using pharmacokinetics and pha ...... patients: a systematic review.
@en
Using pharmacokinetics and pha ...... patients: a systematic review.
@nl
prefLabel
Using pharmacokinetics and pha ...... patients: a systematic review.
@en
Using pharmacokinetics and pha ...... patients: a systematic review.
@nl
P50
P1476
Using pharmacokinetics and pha ...... patients: a systematic review.
@en
P2093
Sandra L Peake
P356
10.1016/J.IJANTIMICAG.2011.07.013
P577
2011-09-16T00:00:00Z